drugset / Trial / NCT02296749

Bioavailability Study of Sirolimus Tablets 2 mg Under Fasting Condition

NCT02296749

Phase 1 Completed 60 enrolled Dr. Reddy's Laboratories Limited
RandomizedCrossoverOpen-labelTreatment

Summary

This study is to assess the Sirolimus Tablets 2 mg of Dr. Reddy's Laboratories Limited, India and Rapamune® (Sirolimus) tablets 2 mg of Wyeth Laboratories, Philadelphia in healthy, adult,human subjects under Fasting conditions.

Timeline

Start
2010-01
Primary completion
2010-01
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 2 mg Oral

Indications

No indication recorded.